Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

por M.   Yu. Fedyanin, L.  Yu.  Vladimirova, V.  A.  Chubenko, L.   A. Zagorskaya, A.  V.  Belyaeva, O.  L.  Fakhrutdinova, S.  A.  Belukhin, A.   S. Zhabina, L.   V. Khalikova, L.  V.  Bolotina, R.   V. Orlova, F.  V.  Moiseenko, G.   Z. Mukhametshina, A.  I.  Khasanova, A.  V.  Belonogov, Kh.  S.  Musaeva, O.  Yu.  Novikova, I.  Yu.  Stradaeva, I.  L.  Popova, S.  P.  Erdniev, A.  K.  Ivanova, A.  V.  Androsova, P.  S.  Feoktistova, E.  S.  Kuzmina, E.   V. Karabina, O.  V.  Nekrasova, O.  V.  Sekhina, A.   A. Mishchenko, L.  A.  Mukova, B.  Kh.  Kertiev, G.  I.  Kosar, S.   N. Osodoeva, A.  I.  Kats, R.  R.  Malina, M.  A.  Lyadova, A.  A.  Tryakin, S.  A.  Tyulandin
Publicado 2022-03-01

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer

por M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin
Publicado 2019-06-01